Posts by: Marta Figueiredo

Marta Figueiredo

Marta Figueiredo holds a BSc in Biology and a MSc in Evolutionary and Developmental Biology from the University of Lisbon, Portugal. She is currently finishing her PhD in Biomedical Sciences at the University of Lisbon, where she focused her research on the role of several signalling pathways in thymus and parathyroid glands embryonic development.

February 22, 2021February 22, 2021

Keytruda-Lenvima Combo Better Than Sutent in Treating Kidney Cancer

News

A combination of Keytruda (pembrolizumab) and Lenvima (lenvatinib) worked better than standard Sutent (sunitinib) at delaying disease progression and prolonging survival in adults with untreated advanced renal cell carcinoma (RCC) ... Read more

February 12, 2021February 12, 2021

FDA Approves Libtayo, 1st Immunotherapy for Advanced Basal Cell Carcinoma

News

The U.S. Food and Drug Administration (FDA) has approved Libtayo (cemiplimab-rwlc), making it the first immunotherapy for people with advanced basal cell carcinoma (BCC) — the most common form of ... Read more

February 3, 2021February 3, 2021

Keytruda Closer to Expanded EU Approval for Resistant Hodgkin’s Lymphoma

News

Keytruda (pembrolizumab) has been recommended for approval in the European Union (EU) to treat adults and children, 3 years and older, with relapsed or refractory classical Hodgkin’s lymphoma (cHL) whose ... Read more

January 11, 2021January 11, 2021

Personalized AV-GBM-1 Vaccine Shows Promise for Aggressive Brain Cancer

News

Adding AIVITA Biomedical’s experimental and personalized cancer vaccine, AV-GBM-1, to post-surgery standard treatment slows disease progression in adults newly diagnosed with glioblastoma — the most aggressive type of brain cancer ... Read more

January 4, 2021January 8, 2021

Triple Combo With Libtayo Shows Promise in Hard-to-treat Brain Cancer

News

Combining two experimental cancer vaccines with Libtayo (cemiplimab) promotes strong anti-tumor immune responses and shows early signs of effectiveness in adults newly diagnosed with glioblastoma — the most aggressive type ... Read more

December 18, 2020December 18, 2020

Tebentafusp Prolongs Life for Those With Advanced Eye Cancer, Trial Finds

News

Immunocore’s investigational immunotherapy tebentafusp (IMCgp100) is superior to investigator’s choice at prolonging the lives of adults newly diagnosed with metastatic uveal melanoma — a common and hard-to-treat form of eye ... Read more

December 14, 2020December 14, 2020

Keytruda Approval Recommended in EU as First-line Therapy for Certain Colorectal Cancers

News

Keytruda (pembrolizumab) has been recommended for approval in the European Union (EU) as a first-line treatment for adults with inoperable or metastatic colorectal cancer with certain genetic features. These include ... Read more

December 11, 2020December 11, 2020

Yescarta Shows Promise in Advanced Non-Hodgkin Lymphomas, Trial Data Show

News

Yescarta (axicabtagene ciloleucel), Kite Pharma’s CAR T-cell therapy, leads to a high rate of strong and sustained responses in adults with relapsed or refractory (resistant) follicular lymphoma, known as FL, or marginal zone ... Read more

December 4, 2020December 4, 2020

Keytruda-Lenvima Combo in Kidney Cancer Better Than Sutent in Improving Survival

News

A combination of Keytruda (pembrolizumab) and Lenvima (lenvatinib) worked better than standard Sutent (sunitinib) in improving survival outcomes among adults with untreated advanced renal cell carcinoma (RCC) — the most ... Read more

November 2, 2020November 2, 2020

Libtayo Given FDA Priority Review for Advanced NSCLC With High PD-L1 Levels

News

The U.S. Food and Drug Administration (FDA) has granted priority review to an application seeking the approval of Libtayo (cemiplimab) as a first-line therapy for advanced non-small cell lung cancer (NSCLC) and high PD-L1 levels, according ... Read more